Myriad Genetics Sees 2024 Adj. EPS $0.00-$0.05 vs $(0.01) Est., Revenue $820M-$840M vs $819.25M Est.
Portfolio Pulse from Benzinga Newsdesk
Myriad Genetics projects its adjusted EPS for 2024 to be between $0.00 and $0.05, surpassing the estimated $(0.01), and forecasts revenue to be between $820M and $840M, slightly above the estimated $819.25M.
February 27, 2024 | 10:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Myriad Genetics projects a positive adjusted EPS and higher revenue for 2024, indicating potential growth and financial improvement.
The positive forecast for both adjusted EPS and revenue suggests an optimistic outlook for Myriad Genetics, likely leading to increased investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100